Collegium Pharmaceutical, Inc.
HealthcareNASDAQ:COLL · NASDAQ Global Select
+$0.30 today
Vol 0.27M · Avg 0.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$796.3M of revenue converted into $74.9M of net income for the selected period. Gross margin is 60.6% and net margin is 9.3%, showing how much revenue survives after costs and taxes. EPS is $2.04, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M +23.6% | $631.4M +11.4% | $566.8M +22.2% | $463.9M +67.6% | $276.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $317.3M +24.9% | $254.1M +5.6% | $240.6M -5.4% | $254.4M +101.5% | $126.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $463.3M +22.8% | $377.3M +15.7% | $326.2M +55.7% | $209.5M +39.1% | $150.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 59.3% -0.4pp | 59.8% +2.2pp | 57.5% +12.4pp | 45.2% -9.2pp | 54.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 -100.0% | $4.0M -57.9% | $9.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $276.2M +50.9% | $183.0M +14.9% | $159.2M -7.5% | $172.2M +44.7% | $119.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $276.2M +33.1% | $207.4M +30.3% | $159.2M -9.6% | $176.2M +32.5% | $133.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $226.1M +33.6% | $169.2M +13.3% | $149.3M +7.4% | $138.9M +101.6% | $68.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $401.0M +17.4% | $341.7M +10.8% | $308.3M +77.9% | $173.3M +100.2% | $86.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 51.4% -2.7pp | 54.1% -0.3pp | 54.4% +17.0pp | 37.4% +6.1pp | 31.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $187.1M +10.1% | $169.9M +1.8% | $167.0M +401.1% | $33.3M +89.0% | $17.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 24.0% -2.9pp | 26.9% -2.6pp | 29.5% +22.3pp | 7.2% +0.8pp | 6.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.3M -19.2% | $14.0M -10.5% | $15.6M +1391.4% | $1.0M +8625.0% | $12.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $82.3M +11.3% | $74.0M -11.2% | $83.3M +31.8% | $63.2M +200.8% | $21.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$94.5M -32.4% | -$71.3M +21.8% | -$91.2M -46.7% | -$62.2M -196.0% | -$21.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $92.6M -6.0% | $98.6M +30.2% | $75.7M +362.5% | -$28.8M -755.0% | -$3.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 11.9% -3.7pp | 15.6% +2.2pp | 13.4% +19.6pp | -6.2% -5.0pp | -1.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $29.7M +1.3% | $29.4M +6.5% | $27.6M +817.2% | -$3.8M +94.9% | -$74.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | $62.9M -9.1% | $69.2M +43.7% | $48.2M +292.6% | -$25.0M -135.0% | $71.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.1% -2.9pp | 11.0% +2.5pp | 8.5% +13.9pp | -5.4% -31.2pp | 25.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 -7.5% | $2 +33.8% | $2 +316.2% | -$1 -136.1% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -7.0% | $2 +44.2% | $1 +274.3% | -$1 -139.8% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $31.7M -1.8% | $32.3M -4.3% | $33.7M -0.3% | $33.8M -3.2% | $34.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $39.7M -1.8% | $40.4M -3.3% | $41.8M +23.5% | $33.8M -17.6% | $41.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Dynavax Technologies Corporation
DVAX
$1.82B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
Innoviva, Inc.
NASDAQ:INVA
$1.68B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Cronos Group Inc.
NASDAQ:CRON
$1.00B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
MiMedx Group, Inc.
NASDAQ:MDXG
$536.20M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does COLL generate?
Collegium Pharmaceutical, Inc. (COLL) reported $780.57M of revenue in fiscal 2025.
Is COLL profitable?
Collegium Pharmaceutical, Inc. (COLL) reported $62.87M of net income, with a net margin of 8.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.